This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About REMICADE® (infliximab)

Updated on 02/07/2019

IMMUNOLOGY

REMICADE has over 19 years of experience of treating patients with immune-mediated diseases in the field of Rheumatology, Gastroenterology and Dermatology1

arrow image

REMICADE (infliximab) becomes the first anti-TNF for CD
after being approved to treat severe, active CD2,3

1999

REMICADE approved for fistulising, active CD2

REMICADE approved for RA4

2000

REMICADE approved for severe, active AS4

2003

REMICADE approved for active and progressive PsA4

2004

REMICADE approved for the treatment of moderately to severely active UC4,5

2006

REMICADE approved for severe, active paediatric CD5

2007

REMICADE approved for moderately active CD5

2011

REMICADE approved for severely active paediatric UC5

2012

Over the past 19 years, REMICADE has been used to treat over 95,000 patients in the UK6*…

…but our commitment to immunology doesn’t end here.

The journey continues...

CD = Crohn's disease; TNF = tumour necrosis factor.

RA = rheumatoid arthritis.

AS = ankylosing spondylitis.

PsA = psoriatic arthritis.

TNF = tumour necrosis factor; UC = ulcerative colitis.

CD = Crohn's disease.

CD = Crohn's disease.

UC = ulcerative colitis.

*Estimated cumulative commercial exposure to REMICADE in RA, PsA, AS, CD, UC and PsO patients from launch to 23 August 2018.
AS = ankylosing spondylitis; CD = Crohn’s disease; PsA = psoriatic arthritis; PsO = psoriasis; RA = rheumatoid arthritis; UC = ulcerative colitis.

What is REMICADE?

REMICADE is a monoclonal antibody; it is a TNFα (Tumour Necrosis Factor–alpha) inhibitor that is indicated for the treatment of a range of immune-mediated inflammatory disorders.1

REMICADE is a prescription-only product. It is presented as powder (100 mg/vial) to be reconstituted with water, diluted with saline and thereafter administered via intravenous infusion.1

About REMICADE

*From launch to August 2018

Further information about REMICADE

Gastroenterology

View more information for Gastroenterology HCP’s

Visit page

Rheumatology

View more information for Rheumatology HCP’s

Visit page

Pharmacy

View more information for pharmacists

Visit page

Patient website

Visit the REMICADE patient website

Visit myREMICADE.co.uk

References

  1. REMICADE Summary of Product Characteristics.
  2. European Medicines Agency. REMICADE: Scientific discussion. December 2005. Available from https://www.ema.europa.eu/en/documents/scientific-discussion/remicade-epar-scientific-discussion_en.pdf.
  3. European Medicines Agency. Humira: Procedural steps taken and scientific information after the authorisation. December 2018. Available from https://www.ema.europa.eu/en/documents/procedural-steps-after/humira-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf.
  4. European Medicines Agency. REMICADE: Steps taken after granting the marketing authorisation. December 2005. Available from https://www.ema.europa.eu/en/documents/steps-after-cutoff/remicade-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf.
  5. European Medicines Agency. REMICADE: Procedural steps taken and scientific information after the authorisation. March 2019. Available from https://www.ema.europa.eu/en/documents/procedural-steps-after/remicade-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf.
  6. MSD data on file [PSUR, GB-MAB-00040 April 2019].

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-MAB-00045 | Date of Preparation: July 2019